期刊文献+

拓扑异构酶Ⅰ抑制剂拓扑替康对MUTZ-1细胞系作用的研究

Experimental research on anti-leukemia effect of topoisomerase Ⅰ inhibitors topotecan on MUTZ-1 cells
原文传递
导出
摘要 目的:研究拓扑替康(TPT)对骨髓增生异常综合征(MDS)急性髓系白血病(AML)M2变细胞系MUTZ-1的作用机制,以及环磷酰胺(CTX)对TPT作用靶标Topo-ⅠmRNA表达水平的影响。方法:MTT法测定TPT对MUTZ-1细胞的杀伤作用。流式细胞术分析TPT对MUTZ-1细胞周期的影响。染色体分析方法观察TPT对MUTZ-1的影响。半定量RT-PCR检测CTX对Topo-ⅠmRNA表达水平的影响。结果:①5、10、20、40、80、160nmol/L TPT与MUTZ-1细胞共培养72h后细胞存活率呈剂量依赖性性下降,分别为(78.9±10.7)%、(69.2±4.7)%、(58.6±7.1)%、(49.9±7.6)%、(42.4±0.8)%和(23.7±9.8)%,各实验组与对照组(505.6±20.1)%之间均差异有统计学意义(均P<0.05)。②TPT阻碍MUTZ-1细胞染色体发生分离,并使MUTZ-1细胞发生G2/M期阻滞,该阻滞呈时间依赖性和剂量依赖性。③半定量RT-PCR发现0.224mmol/LCTX与MUTZ-1细胞共培养24、48和72h后,Topo-ⅠmRNA表达都上升,以48h的表达量最高。结论:TPT对MUTZ-1细胞的生长抑制呈剂量依赖性。染色体分离受阻和G2/M期阻滞是TPT的作用机制之一。CTX可上调Topo-Ⅰ表达,与TPT发挥联合抗白血病作用。 Objective:To explore the anti-leukemia effect of TPT on MUTZ-1 cells(MDS-RAEB transforming to AML cell line)in vitro,and the effect of cyclophosophamide(CTX)on the level of Topo-ⅠmRNA in MUTZ-1 cells.Method:The cytotoxic effect of TPT on MUTZ-1 cells was determined by MTT assay.The changes of cell cycle were observed by FCM with PI staining.The karyotypic changes of TPT on MUTZ-1 cells were observed by karyotyping.The effects of CTX on the level of Topo-ⅠmRNA were determined by hemi-quantitative RT-PCR.Result:①After incubation of MUTZ-1 cell with 5,10,20,40,80 and 160nmol/L TPT for 72h,the survival ratesprogressively reduced to(78.9±10.7)%,(69.2±4.7)%,(58.6±7.1)%,(49.9±7.6)%,(42.4±0.8)% and(23.7±9.8)%(P〈0.05),compared with control(505.6±20.1)%.② FCM with PI staining showed that more MUTZ-1 cells were arrested in G2/M phase,which was time-dependent and dose-dependent.Karyotyping results showed blockage of chromosome segregations.③As revealed by hemi-quantitative RT-PCR there was an increasing trend in the level of Topo-ⅠmRNA in MUTZ-1 treated with 0.224 mmol/L CTX for 24 h,48 h and 72 h.Conclusion:The inhibiting effect of TPT on MUTZ-1 activity is dose-dependent.TPT induces blockage of chromosome segregations and G2/M phase arrest in MUTZ-1 cells.CTX can upregulate the level of Topo-ⅠmRNA,which has synergism with TPT.
出处 《临床血液学杂志》 CAS 2012年第4期457-460,共4页 Journal of Clinical Hematology
关键词 拓扑替康 MUTZ-1细胞 抗白血病 topotecan; MUTZ-1 cell; anti-leukemia;
  • 相关文献

参考文献11

  • 1秦铁军.拓扑替康治疗恶性血液病研究现况[J].国外医学(输血及血液学分册),2002,25(3):240-243. 被引量:6
  • 2NORGAARD J M,LANGKJER S T, PALSHOF T, et al. Pretreatment leukaemia cell drug resistance is correlate to clinical outcome in acute myeloid leukae mia[J]. Eur ] Haematol, 2001,66 : 160- 167.
  • 3ZWAAN C M, KASPERS G J, PIETERS R, et al. Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities[J]. Blood, 2002,100: 3352 - 3360.
  • 4BOFFA L C,SCARFI S, MARIANI M R, et ah Di- hydrotestosterone as a selective cellular/nuclear local- ization vector for anti-gene peptide nucleic acid in prostatic carcinoma cells[J]. Cancer Res, 2000, 60.. 2258-2262.
  • 5KANTARJIAN H M, BERAN M, ELLIS A, et al. Phase I study of Topotecan,a new topoiscimerase I inhibitor,in patients with refractory or relapsed acute leukemia[J]. Blood, 1993,81:1146- 1151.
  • 6WEIHRAUCH M R, STAIB P, SEIBERLICH B, et al. Phase I/II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia[J]. Leuk Lymphoma, 2004,45 : 699 - 704.
  • 7BERAN M, KANTARJIAN H. Topotecan in the treatment of hematologic malignancies[J]. Semin Hematol,1998,35(3 Suppl 4) :26-31.
  • 8KANTARJIAN H, BERAN M, CORTES J, et al. Long-term follow-up results of the combination of to potecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome[J]. Cancer, 2006,106 : 1099 - 1109.
  • 9LEONI F, CIOLLI S, NOZZOLI C, et al. Fludarabine, cytarabine and topotecan(FLAT)as induction therapy for acute myeloid leukemia in the elderly: a prelimina ry report[J]. Haematologica, 2001,86: 104 - 104.
  • 10CORTES J, ESTEY E, BERAN M, et al. Cyclophosphamide, Ara-C and topotecan(CAT)for patients with refractory or relapsed acute leukemia[J]. Leuk Lymphoma,2000,36(5-6) :479-484.

二级参考文献25

  • 1Heron JF. Oncologist, 1998,3:390
  • 2Herben VMM, ten Bokkel Huinink WW, Beijnen JH. Clin Pharmacokinet, 1996,31: 85
  • 3Verweij J,Lund B,Beijnen J,et al .Ann Oncol,1993,4:673
  • 4Rowinsky EK, Grochow LB, Hendricks CB, et al. J Clin Oncol, 1992,10:647
  • 5Burris Ⅲ HA. Semin Hematol,1999,36(suppl 8) :26
  • 6Crump M,Lipton J,Hedley D,et al. Leukemia,1999,13:343
  • 7Kantarjian H,Beran M,Ellis A,et al.Blood 1993,81:1146
  • 8Rowinsky EK,Adjiei R, Donehower RC, et al. J Clin Oncol 1994,12:2193
  • 9Rowinsky EK,Kaufmann SH, Baker SD, et al. Clin Cancer Res, 1996,2:1921
  • 10Beran M,Kantarjian H,O'Brien S,et al.Blood,1996,88:2473

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部